A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

ABSTRACT: Only a minority of patients with high risk lymphoma will be cured with autologous transplant, so maintenance with vorinostat, an oral agent with activity in relapsed lymphoma, was studied starting day + 60 for 21 consecutive days followed by a week off for up to 11 cycles. Twenty-three patients with lymphoma were treated. Ten patients completed the full 11-cycle treatment plan per protocol, four patients were removed due to progressive disease and seven withdrew or were removed from the study due to toxicities. Despite Prevnar vaccine administration every 2 months for three injections, the mean antibody concentration never reached protective levels (> 0.35 μg/mL). Fatigue and functional well-being measured by Brief Fatigue Inventory and Functional Assessment of Cancer Therapy-General impro

SUBMITTER: Hofmeister CC 

PROVIDER: S-EPMC4417026 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature